Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
P/E ratio for Pacira BioSciences, Inc. (PCRX)
P/E ratio as of 2023: 37.17
According to Pacira BioSciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 37.17. At the end of 2022 the company had a P/E ratio of 110.48.
P/E ratio history for Pacira BioSciences, Inc. from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 37.17 |
| 2022 | 110.48 |
| 2021 | 63.44 |
| 2020 | 17.55 |
| 2019 | -170.71 |
| 2018 | -3736.71 |
| 2017 | -42.64 |
| 2016 | -31.67 |
| 2015 | 1511.80 |
| 2014 | -227.33 |
| 2013 | -29.79 |
| 2012 | -10.14 |
| 2011 | -3.28 |
| 2010 | -4.46 |
| 2009 | -0.13 |
| 2008 | -0.09 |